Atai Life Sciences N.V.
ATAI
$4.83
$0.091.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.31M | 1.86M | 308.00K | 331.00K | 378.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.31M | 1.86M | 308.00K | 331.00K | 378.00K |
| Cost of Revenue | 10.84M | 10.84M | 11.23M | 11.23M | 11.23M |
| Gross Profit | -8.53M | -8.98M | -10.92M | -10.90M | -10.85M |
| SG&A Expenses | 46.60M | 45.09M | 46.06M | 54.44M | 57.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.80M | 98.81M | 100.17M | 104.41M | 108.69M |
| Operating Income | -96.49M | -96.95M | -99.86M | -104.08M | -108.31M |
| Income Before Tax | -120.22M | -150.27M | -151.52M | -132.97M | -62.87M |
| Income Tax Expenses | -703.00K | -1.13M | -1.47M | -2.77M | -2.35M |
| Earnings from Continuing Operations | -119.51 | -149.14 | -150.05 | -130.20 | -60.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 109.00K | 149.00K | 780.00K | 1.60M | 2.45M |
| Net Income | -119.40M | -148.99M | -149.27M | -128.60M | -58.07M |
| EBIT | -96.49M | -96.95M | -99.86M | -104.08M | -108.31M |
| EBITDA | -95.74M | -96.34M | -99.39M | -103.73M | -107.97M |
| EPS Basic | -0.70 | -0.91 | -0.93 | -0.80 | -0.36 |
| Normalized Basic EPS | -0.45 | -0.58 | -0.59 | -0.60 | -0.59 |
| EPS Diluted | -0.70 | -0.91 | -0.93 | -0.81 | -0.39 |
| Normalized Diluted EPS | -0.45 | -0.58 | -0.59 | -0.60 | -0.58 |
| Average Basic Shares Outstanding | 694.17M | 657.99M | 640.61M | 638.74M | 633.91M |
| Average Diluted Shares Outstanding | 694.17M | 657.99M | 640.61M | 638.74M | 655.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |